Ratings Galenica AG

Equities

GALE

CH0360674466

Market Closed - Swiss Exchange Other stock markets 11:31:30 2024-04-26 am EDT			5-day change	1st Jan Change
70.85 ^CHF	+0.71%		+0.93%	-2.61%

Apr. 17	Switzerland's Galenica Issues CHF100 Million Bond Due 2031	MT
Mar. 14	GALENICA : FY23 one-offs shroud decent underlying profitability growth

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Over the past twelve months, analysts' opinions have been strongly revised upwards.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company's earnings growth outlook lacks momentum and is a weakness.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
GALENICA AG	-2.61%	3.84B	B
MCKESSON CORPORATION	+17.51%	70.95B	C+
SINOPHARM GROUP CO. LTD.	+5.38%	8.67B	C
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.69%	8.16B	B
HUADONG MEDICINE CO., LTD	-20.96%	7.91B	B-
H. LUNDBECK A/S	+0.49%	4.51B	B-
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+17.12%	4.31B	B+
EBOS GROUP LIMITED	-3.38%	4.07B	B-
CHINA NATIONAL MEDICINES CORPORATION LTD.	+22.08%	3.63B	C+
MEDIPAL HOLDINGS CORPORATION	+7.96%	3.26B	C

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes